Alnylam's Amvuttra shows sustained benefit in five-year ATTR-CM study data

• Alnylam Pharmaceuticals presented five-year HELIOS-B results for Amvuttra in transthyretin amyloidosis with cardiomyopathy at the American Heart Association Scientific Sessions 2026.
• Continuous treatment reduced mortality and cardiovascular events compared with starting treatment approximately three years later.
• Earlier treatment better preserved quality of life, with no new safety signals identified through five years.
• A separate exploratory analysis found Amvuttra preserved exercise capacity over two years compared with placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611091050BIZWIRE_USPR_____20261109_BW441010) on November 09, 2026, and is solely responsible for the information contained therein.